Other

Restructuring charges remaining to be excluded from calculation of consolidated EBITDA

Boston Scientific Restructuring charges remaining to be excluded from calculation of consolidated EBITDA decreased by 31.9% to $77.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 80.8%, from $401.00M to $77.00M.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2019
Last reportedQ3 2025
Metric ID: other_restructuring_charges_remaining_to_be_excluded_fro_9b120e

Historical Data

14 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$467.00M$428.00M$347.00M$311.00M$294.00M$457.00M$416.00M$369.00M$273.00M$453.00M$401.00M$274.00M$113.00M$77.00M
QoQ Change—-8.4%-18.9%-10.4%-5.5%+55.4%-9.0%-11.3%-26.0%+65.9%-11.5%-31.7%-58.8%-31.9%
YoY Change———-33.4%-31.3%+31.7%+33.8%+25.5%-40.3%+8.9%+8.7%+0.4%-75.1%-80.8%
Range$77.00M – $467.00M
CAGR-42.6%
Avg YoY Growth-13.8%
Median YoY Growth+0.4%
Current Streak4 quarters decline

Frequently Asked Questions

What is Boston Scientific's restructuring charges remaining to be excluded from calculation of consolidated ebitda?
Boston Scientific (BSX) reported restructuring charges remaining to be excluded from calculation of consolidated ebitda of $77.00M in Q3 2025.
How has Boston Scientific's restructuring charges remaining to be excluded from calculation of consolidated ebitda changed year-over-year?
Boston Scientific's restructuring charges remaining to be excluded from calculation of consolidated ebitda decreased by 80.8% year-over-year, from $401.00M to $77.00M.